Pipeline

Pipeline

Early Discovery
Lead Optimization
Pre Clinical
Phase 1
Neurodegeneration (NURR1)

LF101 (Lead)

Central-Nervous System Disease 

(1st generation)

Small Molecule (IP)

 

  • 19% 19%
Neurodegeneration (NURR1)

LF102

Parkinson’s Disease (1st generation)

Small Molecule (Oral)

 

  • 40% 40%
Neurodegeneration (NURR1)

LF201

Parkinson’s Disease

(2nd generation)

Small Molecule (Intranasal)

 

  • 40% 40%
Oncology (VRK1)

LF501

VRK1 (IHC 2+) Breast Cancer

VRK1 (IHC 2+) Lung Cancer

Small Molecule Oral (PO)

  • 32% 32%
Metabolic  disorders
(Nor1, NR4R3)

LF601

Type 2 Diabetes

VRK1 (IHC 2+) Lung Cancer

Small Molecule Oral (PO)

  • 32% 32%
Neurodegeneration
(a-Synuclein)

LF701

Dementia with Lewy bodies

Small Molecule Oral (PO)

  • 19% 19%

Neurodegeneration(NURR1)

LF101 (Lead)

Central-Nervous System Disease (1st generation)
Small Molecule (IP)

Discovery

  • 23% 23%

Neurodegeneration(NURR1)

LF102

Parkinson’s Disease (1st generation)
Small Molecule (Oral)

Lead Optimization

  • 45% 45%

Neurodegeneration(NURR1)

LF103

Parkinson’s Disease (2nd generation)
Small Molecule (Intranasal)

Lead Optimization

  • 45% 45%

Oncology  (VRK1)

LF501

VRK1 (IHC 2+) Breast Cancer & Lung Cancer
Small Molecule Oral (PO)

Lead Optimization

  • 40% 40%

Metabolic  disorders (Nor1, NR4R3)

LF601

Type 2 Diabetes
Small Molecule Oral (PO)

Discovery

  • 23% 23%

Neurodegeneration(a-Synuclein)

LF701

Dementia with Lewy bodies
Small Molecule Oral (PO)

Discovery

  • 23% 23%